Thank You for Visiting DIMA Biotech at PEGS & CAS 2025!
We had a fantastic time connecting with researchers, partners, and customers at PEGS Boston and the CAS 2025 Annual Meeting this May. Thank you to everyone who stopped by our booth, attended our talks, or picked up our materials—it was great to meet so many of you in person!
As a follow-up, we’ve created this page to share key resources, highlights, and moments from both conferences. Whether you’d like to revisit our materials or explore our latest innovations, everything is just a click away.
Explore Our Technologies & Platforms
Download our latest brochures, product highlights, and technical posters:
DIMA Highlight
Lead Antibody Molecules
Synthetic Nanodisc
Scan code download
About DIMA BIOTECH
CAS Meeting Poster
Conference Highlights
Check out some snapshots and videos from our time at PEGS and CAS:
Browse our categories
Latest News
STAB1/Stabilin-1: Reprogramming Macrophages to Unlock Tumor Immune Suppression
STAB1 (Stabilin-1) is an emerging immunoregulatory receptor expressed on tumor-associated macrophages. Targeting STAB1-driven macrophage reprogramming [...]
Feb
Over USD 50 Billion! A Global Surge in Pharma BD and M&A Deals in January 2026
January 2026 global pharma BD and M&A activity highlights sustained capital concentration in innovative targets, [...]
Feb
Membrane Protein Antibody Development: Why Nanodiscs Are Reshaping GPCR and Ion Channel Targeting
Membrane proteins are critical drug targets, but their hydrophobic and structurally complex nature has limited [...]
Jan
CDH3/P-cadherin From a Cell Adhesion Molecule to an Emerging Target in Cancer Therapy
Over the past year, Cadherin-3 (CDH3, P-cadherin), traditionally regarded as a classical cell-cell adhesion molecule, [...]
Jan
CDH17 Antibody and Cell Assay Selection Guide Domain, Conformation, and Cross-Species Considerations
Cadherin-17 (CDH17) is a non-classical calcium-dependent adhesion protein predominantly expressed in the intestinal epithelium and [...]
Jan
TSHR as a Strategic Therapeutic Target in Thyroid Diseases
The thyroid-stimulating hormone receptor (TSHR) has re-emerged as a key target in endocrinology and autoimmune [...]
Jan
Over USD 10 Billion! December 2025 Biopharma BD Deal Highlights
In December 2025, global biopharma business development (BD) activity surged toward year-end, reflecting a clear [...]
Jan
From “Immuno-Oncology Star” to Technology Race A Comprehensive Overview of PD-1 Targeted Drug Modalities
Over the past year, the PD-1 immunotherapy landscape has once again witnessed intensive progress. From [...]
Dec
What’s Next?
We’re excited to continue supporting your research through:
Currently, we offer over 500 in-stock Nanodisc products, covering more than 200 membrane protein targets, with a variety of tag options available (such as Flag, MBP, Strep, etc.) to meet diverse experimental needs. In addition to our catalog products, we also provide customized services, including biotin labeling, protein affinity binding analysis(SPR), and more, offering flexible support for your research workflows.
Our Nanodiscs provide a stable, native-like lipid bilayer environment for membrane proteins, making them ideal for applications such as membrane protein stabilization, structural biology(Cryo-EM), ligand screening, and antibody discovery.
Click to read our latest blog about Optimizing GPCR Expression and Purification.
At present, DIMA has developed B cell seed libraries and the corresponding pilot antibody molecules for around 500+ targets for blood tumor, immune checkpoints and solid tumors. All targets have human-rabbit chimeric antibodies, and 50+ targets have completed humanization antibodies developed by our DiLibrary™ display platform.
Contact US
If you missed us at the show or want to follow up, feel free to reach out—we’d love to hear from you!